For example, the presence of mutant KRAS is correlated with resistance to EGFR targeting therapies [13] and decreased lymphocyte infiltration in TCGA and KFSYSCC CRC datasets [10]. The gene discussed is KRAS; the disease is colorectal carcinoma.